
# **MDHHS – MCIR Release Notes**


Version 2023 - MCIR OLTP 2023 9.9.0 - RFC 225206

# Forecasting & Assessment – 11 Items

1. PCV20 after completion of PCV13 and PPSV23 after age 65 should be complete (Ref#2481)



2. Dose 3 of HepB is invalid if interval violation of 16 weeks between dose 1-dose 3, accept dose 4 if intervals are met (Ref# 2506)





Release Date: September 27, 2023

3. Forecast and evaluate updated COVID-19 vaccines for 6 months- 4 years (Ref #2581)

		Immunization		Other							
Series SARS-CoV-2	Dose 1 01/01/2023 COVID-19 PFR-BNT 3mcg/0.2mL 3yrs exactly	Dose 2 01/22/2023 COVID-19 PFR- BNT 3mcg/0.2mL 3yrs	Dose 3 07/12/202: COVID-19 P Bivalent 3mcg/0.2m 3yrs 6mos	3 09/3 FR CO MOI L 3yr	ose 4 25/2023 VID-19 ) 25 mcg s 8mos	Dose 5	Dose 6+	Up-To-Date Next Due 11/20/2023			
Personal Inf	Personal Information/Status										
Name		DO	В			Assassma	nt indicates t	hat vaccinations are			
Patient ID		Ag	Age 3 Years 8 Months				Assessment indicates that vaccinations are overdue and should be administered today if not medically contraindicated.				
Administered \	/accine	Can be give	n today	Dose #	Accelerated	l Reco	mmended	Overdue			
COVID-19 (Mod	derna)	Ĭ	Í	5	11/20/2023	11/20	/2023	11/20/2023			

- Recommended COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised by COVID-19 vaccination history, September 15, 2023
  - o <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-01">https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#table-01</a>
- Timing, spacing, age transitions, and simultaneous administration. September 15, 2023

**Immunizations** 

o <a href="https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#timing-spacing-interchangeability">https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#timing-spacing-interchangeability</a>

\_\_\_\_\_

4. Forecast and Evaluate updated Covid-19 vaccines for 5 through 11-year-olds (Ref #2582)

Series	Dose 1	Dose 2	Dos	se 3	Dos	se 4 Do	ose 5	Dose 6+	Status
SARS-CoV-2	07/01/2022 COVID-19 MOD 50mcg 7yrs 6mos	09/05/2022 COVID-19 MOD 25 mcg ped 7yrs 8mos	MOD E 10mcg	I/2023 ID-19 Bivalent I/0.2mL 6mos					COVID-19 (Pfizer/Moderna DUE NOW
Personal Inf	formation/S	tatus							
	or macion, o								
Name			DOB						
Patient ID		Age 8 Years 8				nths	overdue		that vaccinations are administered today ndicated.
Administered	Vaccine	Can be g	iven too	day I	Dose #	Accelerated	d Re	ecommended	Overdue
	zer/Moderna)	YES			4	09/25/2023	0.0	/25/2023	09/25/2023



5. Forecast and Evaluate COVID-19 vaccine administration for ages 12 years and older (Ref #2583)


		Immuniza		Other						
Series	Dose 1	Dose 2	Dose 3	Dose 4	Dos	e 5 Dose 6+	Status			
	01/28/2021	09/26/2021	04/13/2022	10/03/202			0.01/15 40			
CADC C-V2	COVID-19 PFR	COVID-19	COVID-19	COVID-19			COVID-19			
SARS-CoV-2		PFR 30 mcg	MOD 100 mcg				(Pfizer/Moderna)			
	69yrs 8mos	70yrs 4mos	70yrs 10mos	50mcg/0.5r 71vrs 4mc	_		DUE NOW			
				7 1915 41110	io riyioi	VIIIVO				
Personal Information/Status										
Name			DOB			A				
D. d dD				Assessment indicates that vaccinations are						
Patient ID			Age 72 Ye	ears 4 Mont	ns	S overdue and should be administered today				
						if not medically contrai	ndicated.			
Administered	Vaccine	Can be	given today	Dose#	Accelerated	Recommended	Overdue			
COVID-19 (Pf	izer/Moderna)	YES		7	09/12/2023	09/12/2023	09/12/2023			

6. Forecast and evaluate CVX 303, 304, 305, 314 RSV vaccines for 60 years and older (Ref# 2518)


		Immunizati	Other					
Series	Dose 1	Dose 2	Dose 3	Dose 4	Dose 5	Dose 6+	Status (Sningnx)	
							DUE NOW	
RSV	09/01/2023 RSV vaccine, unspecified 70yrs 11mos						Series Complete	
Dorconal Tr	nformation/Sta	tuc						
Name	normation/sta		DOB					
Hume			505		Assessr	nent indicates t	hat vaccinations are	
Patient ID			Age 70 Yea	rs 11 Months	overdue and should be administered today			
					if not me	edically contrain	ndicated.	
<u>Administere</u>	l Vacçine	Ç <u>an</u> be qi	ven today	Dose # Accele	erațed Re	commended	Overdue.	
RSV		Series Co	mplete					



7. Forecast and evaluate for 0 to 8 months CVX 306 nirsevimab (Beyfortus) 0.5ml (Ref# 2565)



- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
  - o www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm
- 8. Forecast and evaluate for 8-19 months of age CVX 307 RSV nirsevimab (Beyfortus) 1ml (Ref# 2566)






9. Forecast and Evaluate updated Covid-19 vaccines for 5 through 11-year-olds (Ref # 2582)

		Immunizat		Other						
Series	Dose 1	Dose 2	Dose 3	Dos	e 4 Do	ose 5	Dose 6+	Status		
SARS-CoV-2	ARS-CoV-2 07/01/2022 09/05/2022 07/31/2023 COVID-19 COVID-19 COVID-19 MOD 50mcg MOD 25 mcg MOD Bivalent 7yrs 6mos ped 10mcg/0.2mL 7yrs 8mos 8yrs 6mos							COVID-19 (Pfizer/Moderna DUE NOW		
Name			DOB							
							Assessment indicates that vaccinations are			
Patient ID			Age 8 Years 8 Months			overdue and should be administered today				
				if not me	edically contrain	ndicated.				
Administered \	/accine	Can be g	iven today	Dose #	Accelerated	l Re	commended	Overdue		
COVID-19 (Pfiz	er/Moderna)	YES		4	09/25/2023	09/	/25/2023	09/25/2023		

10. Forecast and Evaluate COVID-19 vaccine administration for ages 12 years and older (Ref# 2583)



11. Add CVX 314 RSV vaccine unspec. and 315 RSV MAB, unspec, update name of CVX 304 (Ref# 2593)

#### Add to Historical

- 1. CVX 314 RSV vaccine, unspecified
- 2. CVX 315 RSV MAB unspecified
- 3. Change existing code CVX 304 to RSV, unspecified
- Respiratory Syncytial Virus (RSV) Codes and Crosswalks
  - o <a href="https://www.cdc.gov/vaccines/programs/iis/code-sets.html#rsv">https://www.cdc.gov/vaccines/programs/iis/code-sets.html#rsv</a>



### General – 4 Items

- 1. Ending Inventory Report displaying incorrect values (Ref# 2478)
  - Prior to Release: 24 Unusable is incorrect

Lot Number	Expiration Date	Begin Balance	Doses In	Doses Out	Admins	Brwd/ Rplcd	Unusable LW	Balance	Dose Count	Diff
AS3617B	06/30/2023	24	0	0	0	0	24	0	0	0
TOTAL		24	0	0	0	0	24	0	0	0

Post Release: 20 Unusable and 4 Dose Out is correct

Lot Number	Expiration Date	Begin Balance	Doses In	Doses Out		Admins	Brwd/ Rplcd	Unusable LW		Balance	Dose Count	D
AS3617B	06/30/2023	24	0		4	0	0		20	0	0	
TOTAL		24	0		4	0	0		20	0	0	

- 2. HL7 Vaccine Fund Eligibility Error on new COVID vaccines (Ref# 2594)
  - Issue: HL7 erroring messages with new Covid CVX codes
  - Resolution: HL7 now accepts messages with new Covid CVX codes
- 3. HL7 VXU for Minors must have a Responsible Party (Ref# 1293)
  - **Issue**: If a minor's VXU data is processed through HL7 intake for the first time, and that data did not contain information to designate a responsible party, MCIR accepts the message with no warning of the issue.
  - **Resolution**: Minors must have a responsible party designated on HL7 VXU messaging. When MCIR receives a patient's VXU for a minor, a Next of Kin with a "responsible" relationship type should be present on the message. If not present, a warning will be issued, the information will be accepted.
- 4. HL7 process does not save Race = UNK (Ref# 2470)
  - **Issue:** HL7 contains Race=UNK, the patients record does not contain UNK for race
  - Resolution: HL7 process updated to the patient's record will reflect UNK for race

## Help Desk – 10 Items

If you have questions or need assistance, please contact your Field Representative, MCIR Region, or MCIR SOM Help Desk at MDHHS-MCIRHelp@michigan.gov.

